Human Genome Sciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1992-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.hgsi.com
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
- Conditions
- Therapeutic Treatment of Inhalation Anthrax
- Interventions
- Biological: Raxibacumab
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02016963
Study of Belimumab Administered Subcutaneously to Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT01583530
Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: HGS1025Drug: Placebo
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Registration Number
- NCT01434576
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01013818
- Locations
- 🇬🇧
The Institute of Cancer Research, Belmont, Sutton, Surrey, United Kingdom
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00732940
- Locations
- 🇺🇸
STAT Research, Inc., Dayton, Ohio, United States
🇺🇸Valerious Medical Group Research Center, Long Beach, California, United States
🇲🇽Hospital Central "Igancio Morones Prieto", San Lusi Potosi, Mexico
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT00708006
- Locations
- 🇺🇸
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Stanford University Dept. of Medicine-Oncology, Stanford, California, United States
🇺🇸University of Colorado Health Sciences Center, Aurora, Colorado, United States
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: PlaceboBiological: belimumab
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT00657007
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT00656006
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT00639678
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT00583830
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
🇩🇪Klinikum der Johannes-Gutenberg-Universität Mainz, Mainz, Germany